Panagiotidis G, Stenström A, Lundquist I
Department of Pharmacology, University of Lund, Sweden.
Eur J Pharmacol. 1993 Mar 23;233(2-3):285-90. doi: 10.1016/0014-2999(93)90063-n.
It has been shown that the pancreatic beta-cell monoamines are located in the secretory granules, and that they have an inhibitory influence on insulin secretion. Monoamines are inactivated by the enzyme, monoamine oxidase. We now studied in vivo the relation between adrenergic and cholinergic stimulation, insulin secretion and islet monoamine oxidase activity in the mouse. Monoamine oxidase was assayed with three different substrates, serotonin, dopamine and beta-phenylethylamine. The alpha 2-adrenoceptor agonist, clonidine, induced a moderate inhibition (12-18%) of islet monoamine oxidase activity, accompanied by reduced plasma insulin and elevated plasma glucose levels. The alpha 1-adrenoceptor agonist, phenylephrine, did not induce any changes in these parameters. A marked insulin release following the injection of a maximal dose of the beta 2-adrenoceptor agonist, terbutaline, was accompanied by an increase (30-50%) in islet monoamine oxidase activity. The largest increase in monoamine oxidase activity was observed with serotonin as substrate (50%). These effects on insulin secretion and monoamine oxidase activity could not be blocked by clonidine. Similarly, injection of the non-selective alpha-adrenoceptor agonist, adrenaline, which unlike clonidine does not penetrate the blood-brain barrier, had no effect on insulin release induced by a maximal dose of the nonselective beta-adrenoceptor agonist, isoprenaline. Adrenaline, however, markedly suppressed the insulin release induced by a maximal dose of glucose. Cholinergic muscarinic stimulation by a maximal insulin releasing dose of carbachol did not affect islet monoamine oxidase activity. The results suggest that beta 2-adrenoceptor stimulation of islet monoamine oxidase activity reduced the monoamine content and thereby facilitated the release of insulin.(ABSTRACT TRUNCATED AT 250 WORDS)
研究表明,胰腺β细胞中的单胺位于分泌颗粒中,并且它们对胰岛素分泌具有抑制作用。单胺可被单胺氧化酶灭活。我们现在在小鼠体内研究了肾上腺素能和胆碱能刺激、胰岛素分泌与胰岛单胺氧化酶活性之间的关系。用三种不同的底物,即5-羟色胺、多巴胺和β-苯乙胺来测定单胺氧化酶。α2肾上腺素能受体激动剂可乐定可使胰岛单胺氧化酶活性产生中度抑制(12%-18%),同时伴有血浆胰岛素水平降低和血糖水平升高。α1肾上腺素能受体激动剂去氧肾上腺素未引起这些参数的任何变化。注射最大剂量的β2肾上腺素能受体激动剂特布他林后出现明显的胰岛素释放,同时胰岛单胺氧化酶活性增加(30%-50%)。以5-羟色胺为底物时,观察到单胺氧化酶活性增加幅度最大(50%)。可乐定无法阻断这些对胰岛素分泌和单胺氧化酶活性的影响。同样,注射非选择性α肾上腺素能受体激动剂肾上腺素(与可乐定不同,它不能穿透血脑屏障),对最大剂量的非选择性β肾上腺素能受体激动剂异丙肾上腺素诱导的胰岛素释放没有影响。然而,肾上腺素可显著抑制最大剂量葡萄糖诱导的胰岛素释放。最大胰岛素释放剂量的卡巴胆碱引起的胆碱能毒蕈碱刺激不影响胰岛单胺氧化酶活性。结果表明,β2肾上腺素能受体对胰岛单胺氧化酶活性的刺激降低了单胺含量,从而促进了胰岛素的释放。(摘要截短于250词)